PROGRAM CHAIR & FACULTY PRESENTER
Erica L. Mayer, MD, MPH
Director, Breast Cancer Clinical Research
Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts
PROGRAM OVERVIEW
This enduring continuing education activity is designed to explore the potential of novel, oral endocrine therapies (ET) as first-line therapy for ET-sensitive, hormone-receptor-positive (HR+), HER2-negative metastatic breast cancer. A renowned breast cancer expert will guide you through the latest relevant clinical trial efficacy and safety data in the context of current standards of care. This interactive, case-based program will include a review and discussion of novel ETs, implications of frontline use of oral selective estrogen receptor degraders in overall treatment planning, use of molecular testing to guide biomarker-informed decision making, and best practices in adverse event mitigation, including patient counseling, prevention, monitoring, recognition, and multidisciplinary team care.
TARGET AUDIENCE
This educational activity is intended to meet the educational needs of community oncologists and advanced practice providers who manage patients with advanced breast cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the limitations of standard-of-care endocrine therapies and therapeutic advantages of novel SERDs in the treatment of HR+/HER2- metastatic breast cancer.
- Incorporate the latest clinical trial evidence on emerging oral SERDs into treatment planning to optimize treatment decisions for patients with HR+/HER2- metastatic breast cancer.
- Interpret molecular testing results to guide biomarker-informed treatment decisions for patients with HR+/HER2- metastatic breast cancer.
- Apply knowledge of the toxicity profiles of novel SERDs in HR+/HER2- metastatic breast cancer to recognize, anticipate, and mitigate adverse events, including making appropriate referrals to specialists (e.g., cardiology, ophthalmology).
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Erica L. Mayer, MD, MPH | Consulting Fee: AstraZeneca Pharmaceuticals, Atkis, Genentech/Roche, Lilly, and Novartis |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer-reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Kim Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation & Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- La Donna Lue Winston, MSN, APRN, AGACNP-BC, SCRN, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Jessica McMullen, MPH, Program Director for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 07, 2025
EXPIRATION DATE: November 07, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
